The Latest Clinical Evidence on Lactobacillus Species
Lactobacillus is linked to to better H. pylori treatment alongside antibiotics and shorter respiratory infections in children, with promising results for blood sugar, body weight and mood.

Key takeaways
- Lactobacillus has its strongest evidence as an add-on to antibiotics for H. pylori, where it was linked to higher clearance rates and fewer side effects such as diarrhoea.
- In children with respiratory infections, Lactobacillus was linked to a shorter illness.
- Trials also link certain Lactobacillus strains, or blends containing them, to better blood sugar and cholesterol, lower body weight and fewer depressive symptoms.
- Effects depend on the strain, so look for the strain code on a label (such as DSM 17938), because results from one strain do not carry over to another.
- Many Lactobacillus species were renamed in 2020, so your label may show a new name such as Lacticaseibacillus rhamnosus for the same bacterium.
The Latest Clinical Evidence on Lactobacillus
Members of the genus Lactobacillus are lactic acid bacteria commonly used in probiotic supplements, particularly for supporting digestive health. However, recent clinical research is exploring their potential benefits beyond the digestive system, either as individual strains or in combination with other probiotic bacteria.
The latest meta-analyses give the clearest support for Lactobacillus taken alongside antibiotics for Helicobacter pylori infection [1, 2]. The evidence is moderate for shorter respiratory infections in children [3] , and weaker or mixed for abdominal pain in children [4]. Trials also link Lactobacillus, or probiotic blends containing it, to better blood sugar and cholesterol [5], lower body weight [6] and fewer depressive symptoms [7, 8].
What are Lactobacillus species?
Lactobacillus is a genus, a group of closely related bacterial species, whose members make lactic acid from sugars. Many strains of these species are sold as probiotics, which are live microorganisms that give a health benefit when taken in adequate amounts. For a closer look at what they do in your gut, read our Bacterial Spotlight on Lactobacillus.
Why were Lactobacillus species renamed in 2020?
A 2020 taxonomic review published in the International Journal of Systematic and Evolutionary Microbiologysplit the former Lactobacillus genus into 25 genera [9].
The reclassification was based on advances in genetic testing, particularly whole-genome sequencing, which allowed researchers to compare the DNA of different bacterial species in greater detail. They found that many species previously classified under Lactobacillus were genetically quite different and did not belong to one closely related group. These bacteria also differed in their preferred environments, such as living in humans and animals, insects or plants, as well as in their metabolic characteristics [9].
As a result, some familiar species received new names, while others retained their original names. For example:
- Lactobacillus rhamnosus was renamed Lacticaseibacillus rhamnosus.
- Lactobacillus plantarum was renamed Lactiplantibacillus plantarum.
- Lactobacillus reuteri was renamed Limosilactobacillus reuteri.
- Lactobacillus casei was renamed Lacticaseibacillus casei.
- Lactobacillus acidophilus retained its original name.
The new names group species by their genetic relationships, which helps researchers study each group'scharacteristics and potential health benefits more accurately. For you, this means that some probiotic products may display updated bacterial names on their labels, even though the bacterial strains themselves have not changed [9].
Why does the strain matter?
A species such as Limosilactobacillus reuteri contains different strains, which are specific variants identified by codes such as DSM 17938. The effects of probiotics are strain-specific, meaning that findings from one strain cannot automatically be applied to another strain, even within the same species. Many clinical trials included in meta-analyses investigate different probiotic strains or combinations, making it difficult to determine which individual strain is responsible for the observed benefits or which strain may be most effective [1].
What does the latest clinical evidence show?
The studies below are meta-analyses of randomised controlled trials across different conditions and treatment combinations.
Helicobacter pylori treatment
In two recent meta-analyses, adding Lactobacillus to antibiotic treatment for Helicobacter pylori (H. pylori) was associated with higher clearance rates and fewer side effects [1, 2]. H. pylori is a stomach bacterium associated with chronic gastritis and peptic ulcers1.
A 2026 review analysed 32 clinical trials involving 4,010 people to investigate whether adding Lactobacillus supplements to standard antibiotic treatment could improve treatment outcomes [2].
The researchers found that 83.64% of people who took Lactobacillus alongside antibiotics successfully cleared the infection, compared with 75.55% of those who took antibiotics alone. However, subgroup analyses found that the improvement in eradication rates was significant only when Lactobacillus was added to standard triple therapy (an acid-reducing medicine plus two antibiotics) [2].
People taking Lactobacillus also had a lower risk of side effects overall, with fewer reports of diarrhoea, nausea and heartburn [2].
An earlier 2025 review of 14 clinical trials involving 2,054 adults also found that adding Lactobacillus supplements to antibiotic treatment was associated with higher infection clearance and a lower risk of diarrhoea and taste disturbances [1].
Respiratory infections in children
A 2026 network meta-analysis, which compares several treatments at once, pooled randomised trials ofprobiotics for respiratory tract infections in children [3]. It found moderate-certainty evidence that Lactobacillus was associated with a shorter illness overall. Bifidobacterium had moderate-to-high certainty evidence for a shorter cough. Lactobacillus and Bifidobacterium taken together were associated with larger reductions in cough duration and antibiotic use, but the certainty was low to moderate, so this does not show that combining them works better.
Children with abdominal pain
Functional abdominal pain disorders are conditions characterised by recurrent abdominal pain that is not explained by another identifiable medical condition [4]. A 2026 meta-analysis pooled seven randomised controlled trials in 513 children and adolescents that tested Limosilactobacillus reuteri DSM 17938 (formerly Lactobacillus reuteri DSM 17938) against placebo [4]. Treatment lasted 4 to 12 weeks, at 100 million or 200 million colony-forming units (CFU), a count of live bacteria, a day [4].
At the end of treatment, the analysis found a reduction in pain severity compared with placebo. However, this finding did not hold up in sensitivity analyses, which retest a result under stricter assumptions, and no significant difference in pain severity or frequency was observed four weeks after treatment ended. Overall, the evidence does not support a consistent beneficial effect of L. reuteri DSM 17938 for this condition, with certainty ranging from low to very low [4]. The trials were conducted in Italy, Iran, Israel, Greece, Slovenia, Poland and Croatia, with none conducted in Southeast Asia.
Blood sugar and cholesterol
A 2025 network meta-analysis found that certain probiotic formulations containing Lactobacillus species were associated with better metabolic markers in people with type 2 diabetes [5]. Yoghurt containing Lacticaseibacillus casei (formerly Lactobacillus casei) was associated with the largest reduction in insulin resistance, a measure of how poorly the body responds to insulin. Limosilactobacillus reuteri ADR-1 (formerly Lactobacillus reuteri) and Lacticaseibacillus paracasei (formerly Lactobacillus paracasei) were associated with lower LDL cholesterol. Network meta-analyses combine direct and indirect comparisons, so these strain-level results need confirmation in trials that compare the strains head-to-head.
Body weight
A 2024 meta-analysis of nine randomised controlled trials found that supplementation with Lactiplantibacillus plantarum (formerly Lactobacillus plantarum) was associated with reductions in body weight and BMI among adults [6].
Mental health
A 2026 meta-analysis of nine clinical trials in 460 adults with depressive disorders found that probiotic supplementation was associated with a modest reduction in depressive symptoms [8]. Some of the formulations included Lactobacillus strains alongside other bacteria such as Bifidobacterium, so the result reflects probiotics overall rather than Lactobacillus alone. In a randomised, placebo-controlled study, supplementation with Lactiplantibacillus plantarum 299v alongside antidepressant treatment was associated with improvements in certain cognitive functions and reduced kynurenine concentrations, a metabolite involved in the tryptophan pathway [7]. A subsequent metabolomics analysis of L. plantarum 299v supplementation identified changes in several metabolic markers associated with mitochondrial function, inflammation and oxidative stress10. While these findings offer insight into the potential role of Lactobacillus in the gut–brain connection, they do not establish that it can directly improve depressive symptoms. More clinical research is needed, and probiotics should not replace prescribed medication or professional mental health support.
What are the limitations of this evidence?
- Strains differ. Benefits observed with one probiotic strain cannot automatically be applied to another strain, even within the same species. Some studies included in the meta-analyses also did not provide sufficient strain-level information.
- Trials differ. Inconsistencies in study design, tested probiotic strains, clinical outcomes and measurements hinder direct comparisons.
- Combination treatment. Lactobacillus was often administered alongside Bifidobacterium species. In these studies, it can be difficult to isolate the individual contribution of Lactobacillus to the observed effects.
- Certainty varies. The authors rate the H. pylori eradication result as high certainty and the abdominal pain results as low to very low.
- Southeast Asian populations are under-represented. The geographical distribution of clinical trials varied across the reviews. Although some studies included participants from Asian countries, evidence specifically involving Southeast Asian populations remains limited. For example, the respiratory infection review included a Malaysian trial, but findings from a small number of studies may not fully represent the wider Southeast Asian population.
Frequently asked questions
References
- 1.Azam, A., Qureshi, M. A. M., Zahoor, H. S., Raza, S. M., Khan, M. M., Naeem, U., Atif, S., & Waheed, A. (2025). A systematic review and meta-analysis of randomized controlled trials on the benefits of using Lactobacillus supplements as an adjunct treatment for Helicobacter pylori eradication. MicrobiologyOpen, 14(6), Article e70166. https://doi.org/10.1002/mbo3.70166
- 2.Moore, K. M. H., Santo, P., Holanda, E. U., Nau, A. L., & Meine, G. C. (2026). Effectiveness of Lactobacillus-supplemented eradication therapy for Helicobacter pylori: A systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 82(10), Article 258. https://doi.org/10.1007/s00228-026-04186-5
- 3.Na, F., Wang, Y., Zhou, L., Wang, B., Lian, J., & Xu, X. (2026). Comparative efficacy and safety of probiotic for respiratory tract infections in children: A network meta-analysis. Frontiers in Nutrition, 13, Article 1902533. https://doi.org/10.3389/fnut.2026.1902533
- 4.Rodríguez-Brown, F., Guerra Valencia, J., & Hernández-Vásquez, A. (2026). Efficacy and safety of Lactobacillus reuteri DSM 17938 in pediatric functional abdominal pain disorders: A systematic review and meta-analysis of randomized controlled trials. Nutrients, 18(17), Article 2795. https://doi.org/10.3390/nu18172795
- 5.Allam, A. R., Helal, M. B., Alhateem, M. S., Shehab, M. A., Elshaar, A. G., Saeda, M. A., Ibrahim, F. M., Khalil, A. M., & Mahmoud, A. M. (2025). Network meta-analysis of randomized control trials evaluating the effectiveness of various probiotic formulations in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome, 17, Article 265. https://doi.org/10.1186/s13098-025-01841-2
- 6.Li, C.-P., Chen, C.-C., Hsiao, Y., Kao, C.-H., Chen, C.-C., Yang, H.-J., & Tsai, R.-Y. (2024). The role of Lactobacillus plantarum in reducing obesity and inflammation: A meta-analysis. International Journal of Molecular Sciences, 25(14), Article 7608. https://doi.org/10.3390/ijms25147608
- 7.Rudzki, L., Ostrowska, L., Pawlak, D., Małus, A., Pawlak, K., Waszkiewicz, N., & Szulc, A. (2019). Probiotic Lactobacillus plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo-controlled study. Psychoneuroendocrinology, 100, 213–222. https://doi.org/10.1016/j.psyneuen.2018.10.010
- 8.Zhang, Y.-S., Zhang, L.-S., Zhang, K., & Liu, X.-L. (2026). Clinical effects of probiotic supplementation on depressive symptom severity in adults with depressive disorders: A systematic review and meta-analysis. Frontiers in Nutrition, 13, Article 1900466. https://doi.org/10.3389/fnut.2026.1900466
- 9.Zheng, J., Wittouck, S., Salvetti, E., Franz, C. M. A. P., Harris, H. M. B., Mattarelli, P., O'Toole, P. W., Pot, B., Vandamme, P., Walter, J., Watanabe, K., Wuyts, S., Felis, G. E., Gänzle, M. G., & Lebeer, S. (2020). A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. International Journal of Systematic and Evolutionary Microbiology, 70(4), 2782–2858. https://doi.org/10.1099/ijsem.0.004107
- 10.Godzien, J., Kalaska, B., Rudzki, L., Barbas-Bernardos, C., Swieton, J., Lopez-Gonzalvez, A., Ostrowska, L., Szulc, A., Waszkiewicz, N., Ciborowski, M., García, A., Kretowski, A., Barbas, C., & Pawlak, D. (2025). Probiotic Lactobacillus plantarum 299v supplementation in patients with major depression in a double-blind, randomized, placebo-controlled trial: A metabolomics study. Journal of Affective Disorders, 368, 180–190. https://doi.org/10.1016/j.jad.2024.09.058
This article is for general information and does not replace advice from your doctor. Speak to a healthcare professional before making changes to your treatment.
Written
Written by
Vithyaa Rajoo
Reviewed by
Kimberly Foo



